New hope for aggressive leukemia? drug combo targets tough genetic mutation
Disease control
Not yet recruiting
This early-stage study tests a new drug called axatilimab added to standard chemotherapy for people with a specific, high-risk form of acute myeloid leukemia (AML) that has a TP53 mutation or deletion. The goal is to find the safest dose of axatilimab and see how well the combina…
Phase: PHASE1 • Sponsor: Northside Hospital, Inc. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC